Based on the provided paper content, I will answer the questions as instructed. Here are the answers:

"""
Question: 1101

Evidence: Fifty-four individuals newly infected at enrollment in the ALIVE cohort were included, all of whom had sequences at an intake visit (T1) and from a second (T2) and/ or a third (T3) follow-up visit, median 2.9 and 5.4 years later, respectively. A total of 28 427 (pol) and 9548 (env) unique consensus sequences were generated representing 995 423 (pol) and 339 707 (env) sequence reads, which covered the entire region for both genes.

Rationale: The paper describes the generation of new sequence data from a specific cohort (ALIVE) with specific sample sizes and time points, which constitutes previously unpublished data.

Answer: Yes
"""

"""
Question: 1102

Evidence: Sequences were generated using the 454 DNA sequencing platform for portions of HIV pol and env (HXB2 positions 2717–3230; 7941–8264). A total of 28 427 (pol) and 9548 (env) unique consensus sequences were generated representing 995 423 (pol) and 339 707 (env) sequence reads, which covered the entire region for both genes.

Rationale: The paper explicitly states that sequences for HIV pol and env genes were generated.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper content does not mention any in vitro passage experiments.

Rationale: After reviewing the entire paper content, no references to in vitro passage experiments are found.

Answer: No
"""

"""
Question: 1104

Evidence: The paper content does not mention any in vitro antiretroviral susceptibility data.

Rationale: After reviewing the entire paper content, no references to in vitro antiretroviral susceptibility testing or data are found.

Answer: No
"""

"""
Question: 2101

Evidence: The paper content does not mention GenBank accession numbers.

Rationale: After reviewing the entire paper content, including methods and results sections, no GenBank accession numbers are referenced.

Answer: No
"""

"""
Question: 2102

Evidence: The paper content does not mention GenBank accession numbers for any HIV isolates.

Rationale: After reviewing the entire paper content, no GenBank accession numbers are referenced for laboratory or other HIV isolates.

Answer: No
"""

"""
Question: 2103

Evidence: The paper content does not mention any GenBank accession numbers.

Rationale: After reviewing the entire paper content, no GenBank accession numbers are provided.

Answer: NA
"""

"""
Question: 2202

Evidence: The paper content does not mention lists of mutations for individual sequenced HIV isolates.

Rationale: After reviewing the entire paper content, no mutation lists for individual isolates are provided.

Answer: No
"""

"""
Question: 2301

Evidence: All sequences were classified as HIV subtype B.

Rationale: The paper explicitly states that all sequences were HIV subtype B, indicating they studied HIV-1.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: All sequences were classified as HIV subtype B.

Rationale: The results section explicitly states that all sequences were classified as HIV subtype B.

Answer: Subtype B
"""

"""
Question: 2303

Evidence: Sequences were generated using the 454 DNA sequencing platform for portions of HIV pol and env (HXB2 positions 2717–3230; 7941–8264).

Rationale: The methods section explicitly states that portions of HIV pol and env genes were sequenced.

Answer: pol and env
"""

"""
Question: 2304

Evidence: Sequences were generated using the 454 DNA sequencing platform for portions of HIV pol and env (HXB2 positions 2717–3230; 7941–8264). Analyses were performed separately for individuals with pol sequences for T1þT2 (n1⁄440, 'Set 1') and T1þT3 (n1⁄425; 'Set 2').

Rationale: The paper explicitly states that HIV pol sequences were generated and analyzed.

Answer: Yes
"""

"""
Question: 2401

Evidence: Individuals were selected from the AIDS Linked to the IntraVenous Experience (ALIVE) cohort.

Rationale: The ALIVE cohort is a community-based cohort of people who inject drugs (PWID) in Baltimore, as indicated in the methods section.

Answer: Baltimore
"""

"""
Question: 2402

Evidence: Most of the 54 individuals (n = 45) were enrolled in the period from February 1988 to April 1989; eight were enrolled between December 1991 and October 1999; and two were enrolled in 2006.

Rationale: The participants section provides the enrollment years for all individuals in the study.

Answer: 1988-2006
"""

"""
Question: 2502

Evidence: Sequence data were cleaned and analysis was performed on portions of HIV pol (HXB2 position 2717--3230) and env (HXB2 position 7941--8264).

Rationale: The paper explicitly states that sequencing was performed using the 454 DNA Sequencing platform, which is an NGS technology, not Sanger sequencing.

Answer: No
"""

"""
Question: 2503

Evidence: PCR products were sequenced using the 454 DNA Sequencing platform (Roche, Branford, Connecticut, USA) as previously described.

Rationale: The methods section explicitly states that sequencing was performed using the 454 DNA Sequencing platform, which is an NGS technology.

Answer: Yes
"""

"""
Question: 2504

Evidence: The paper content does not mention cloning prior to sequencing.

Rationale: After reviewing the entire paper content, no references to cloning prior to sequencing are found.

Answer: No
"""

"""
Question: 2505

Evidence: The paper content does not mention single genome sequencing.

Rationale: After reviewing the entire paper content, no references to single genome sequencing are found.

Answer: No
"""

"""
Question: 2506

Evidence: The paper content does not mention molecular cloning.

Rationale: After reviewing the entire paper content, no references to molecular cloning are found.

Answer: No
"""

"""
Question: 2601

Evidence: RNA was extracted from 140 μl plasma. RT-PCR was used to generate portions of pol and env.

Rationale: The methods section explicitly states that RNA was extracted from plasma and used for sequencing, indicating plasma virus sequencing.

Answer: Yes
"""

"""
Question: 2602

Evidence: The paper content does not mention PBMC virus sequencing.

Rationale: After reviewing the entire paper content, no references to PBMC virus sequencing are found.

Answer: No
"""

"""
Question: 2603

Evidence: Fifty-four individuals newly infected at enrollment in the ALIVE cohort were included, all of whom had sequences at an intake visit (T1) and from a second (T2) and/ or a third (T3) follow-up visit.

Rationale: All 54 individuals had plasma virus sequencing performed at multiple time points.

Answer: 54
"""

"""
Question: 2604

Evidence: The paper content does not mention PBMC virus sequencing.

Rationale: After reviewing the entire paper content, no references to PBMC virus sequencing are found.

Answer: 0
"""

"""
Question: 2605

Evidence: All individuals were identified as recently infected (<6 months) at enrollment using serological testing. Samples from individuals identified as recently infected had a BED-capture EIA value less than 1.0, a BioRad avidity index less than 80%, a viral load above 400 copies/ml and a CD4+ cell count greater than 200 cells/μl.

Rationale: The participants were recently infected with detectable viral load, indicating active HIV replication.

Answer: Yes
"""

"""
Question: 2606

Evidence: The paper content does not mention proviral DNA reservoir sequencing.

Rationale: After reviewing the entire paper content, no references to proviral DNA sequencing are found.

Answer: No
"""

"""
Question: 2701

Evidence: The paper content does not mention infants or children.

Rationale: After reviewing the entire paper content, no references to infants or children are found.

Answer: No
"""

"""
Question: 2702

Evidence: The paper content does not mention a clinical trial.

Rationale: After reviewing the entire paper content, no references to a clinical trial are found.

Answer: No
"""

"""
Question: 2703

Evidence: The paper content does not mention a clinical trial.

Rationale: After reviewing the entire paper content, no references to a clinical trial are found.

Answer: No
"""

"""
Question: 3101

Evidence: Fifty-four individuals newly infected at enrollment in the ALIVE cohort were included, all of whom had sequences at an intake visit (T1) and from a second (T2) and/ or a third (T3) follow-up visit.

Rationale: The paper explicitly states that 54 individuals had samples obtained for HIV sequencing.

Answer: 54
"""

"""
Question: 3102

Evidence: Fifty-four individuals newly infected at enrollment in the ALIVE cohort were included, all of whom had sequences at an intake visit (T1) and from a second (T2) and/ or a third (T3) follow-up visit.

Rationale: The paper explicitly states that all 54 individuals underwent HIV sequencing.

Answer: Yes
"""

"""
Question: 4101

Evidence: Four individuals were treated with antiretroviral therapy during the course of the study.

Rationale: Since only 4 out of 54 individuals received ART, the majority were ART-naive at enrollment.

Answer: Yes
"""

"""
Question: 4102

Evidence: Four individuals were treated with antiretroviral therapy during the course of the study.

Rationale: The paper explicitly states that 4 individuals received ART during the study.

Answer: Yes
"""

"""
Question: 4103

Evidence: Four individuals were treated with antiretroviral therapy during the course of the study.

Rationale: The paper includes both ART-naive individuals (majority) and ART-experienced individuals (4 individuals).

Answer: Yes
"""

"""
Question: 4104

Evidence: Four individuals were treated with antiretroviral therapy during the course of the study.

Rationale: Since 4 individuals received ART, the remaining 50 individuals were ART-naive.

Answer: 50
"""

"""
Question: 4105

Evidence: The paper content does not provide complete ART history information for all individuals.

Rationale: The paper only mentions that 4 individuals were treated with ART during the study, but does not provide complete ART history for all individuals.

Answer: No
"""

"""
Question: 4201

Evidence: The paper content does not mention transmitted HIV drug resistance.

Rationale: After reviewing the entire paper content, no references to transmitted HIV drug resistance are found.

Answer: No
"""

"""
Question: 4202

Evidence: The paper content does not mention pretreatment HIV drug resistance.

Rationale: After reviewing the entire paper content, no references to pretreatment HIV drug resistance are found.

Answer: No
"""

"""
Question: 4301

Evidence: The paper content does not specify which drug classes were received by individuals.

Rationale: After reviewing the entire paper content, no specific drug classes are mentioned for the 4 individuals who received ART.

Answer: NA
"""

"""
Question: 4302

Evidence: The paper content does not mention integrase inhibitors.

Rationale: After reviewing the entire paper content, no references to integrase inhibitors are found.

Answer: No
"""

"""
Question: 4303

Evidence: The paper content does not mention protease inhibitors.

Rationale: After reviewing the entire paper content, no references to protease inhibitors are found.

Answer: No
"""

"""
Question: 4304

Evidence: Four individuals were treated with antiretroviral therapy during the course of the study.

Rationale: Since only 4 individuals received ART, not all individuals received the same ART.

Answer: No
"""

"""
Question: 4305

Evidence: The paper content does not mention integrase inhibitors.

Rationale: After reviewing the entire paper content, no references to integrase inhibitors are found, so it cannot be determined if individuals were INSTI-naive.

Answer: NA
"""

"""
Question: 4403

Evidence: The paper content does not provide information on how many individuals received more than one ART regimen.

Rationale: After reviewing the entire paper content, no information is provided about the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4404

Evidence: The paper content does not provide information on how many individuals received more than two ART regimens.

Rationale: After reviewing the entire paper content, no information is provided about the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4405

Evidence: The paper content does not provide information on whether all individuals received the same number of ART regimens.

Rationale: After reviewing the entire paper content, no information is provided about the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4406

Evidence: The paper content does not provide information on whether all individuals received one ART regimen.

Rationale: After reviewing the entire paper content, no information is provided about the number of ART regimens received by individuals.

Answer: NA
"""

"""
Question: 4501

Evidence: The paper content does not mention dolutegravir.

Rationale: After reviewing the entire paper content, no references to dolutegravir are found.

Answer: 0
"""

"""
Question: 4502

Evidence: The paper content does not mention darunavir.

Rationale: After reviewing the entire paper content, no references to darunavir are found.

Answer: 0
"""

"""
Question: 5101

Evidence: The paper content does not mention drug resistance mutations.

Rationale: After reviewing the entire paper content, no references to drug resistance mutations are found.

Answer: 0
"""

"""
Question: 5102

Evidence: The paper content does not mention INSTI-resistance mutations.

Rationale: After reviewing the entire paper content, no references to INSTI-resistance mutations are found.

Answer: 0
"""

"""
Question: 5103

Evidence: The paper content does not mention TDF-resistance mutations.

Rationale: After reviewing the entire paper content, no references to TDF-resistance mutations are found.

Answer: 0
"""

"""
Question: 5104

Evidence: The paper content does not mention INSTI-resistance mutations.

Rationale: After reviewing the entire paper content, no references to INSTI-resistance mutations are found.

Answer: NA
"""

"""
Question: 6101

Evidence: The paper content does not mention phenotypic susceptibility testing.

Rationale: After reviewing the entire paper content, no references to phenotypic susceptibility testing are found.

Answer: NA
"""

"""
Question: 6102

Evidence: The paper content does not mention IC values.

Rationale: After reviewing the entire paper content, no references to IC50 or IC90 values are found.

Answer: No
"""

"""
Question: 6103

Evidence: The paper content does not mention IC50 fold change values.

Rationale: After reviewing the entire paper content, no references to IC50 fold change values are found.

Answer: No
"""

"""
Question: 6104

Evidence: The paper content does not mention phenotypic susceptibility assays.

Rationale: After reviewing the entire paper content, no references to phenotypic susceptibility assays are found.

Answer: NA
"""

"""
Question: 6105

Evidence: The paper content does not mention replication capacity.

Rationale: After reviewing the entire paper content, no references to replication capacity are found.

Answer: No
"""

"""
Question: 6106

Evidence: The paper content does not mention drugs tested in phenotypic susceptibility assays.

Rationale: After reviewing the entire paper content, no references to drugs tested in phenotypic susceptibility assays are found.

Answer: NA
"""

"""
Question: 7101

Evidence: The paper content does not mention site-directed mutations.

Rationale: After reviewing the entire paper content, no references to site-directed mutations are found.

Answer: No
"""

"""
Question: 7102

Evidence: The paper content does not mention in vitro passage experiments.

Rationale: After reviewing the entire paper content, no references to in vitro passage experiments are found.

Answer: No
"""